Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Yasser R Abou MouradMohamed A Kharfan-Dabaja

Abstract

Allogeneic hematopoietic cell transplantation in first complete remission (CR1) is considered the standard of care, and the only established therapy that offers a possibility of cure for patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Unfortunately, a number of patients, with suitable HLA-matched donors, are unable to receive an allograft because they fail to respond, or relapse shortly after induction chemotherapy. Incorporating imatinib during the induction/consolidation phase is facilitating a higher number of potentially curative allografts by improving both remission rates and/or the durability of responses in patients with Ph+ ALL. Imatinib and other tyrosine kinase inhibitors are also improving outcomes in elderly patients with Ph+ ALL, ineligible for allografting, when combined with glucocorticoids, and/or conventional chemotherapy. The addition of imatinib or other tyrosine kinase inhibitors to the therapeutic armamentarium of Ph+ ALL is reshaping the treatment algorithm and improving prognosis of this dreadful disease.

References

Sep 21, 2000·Critical Reviews in Oncology/hematology·D Hoelzer, N Gökbuget
Mar 22, 2001·Hematology/oncology Clinics of North America·J P Radich
Sep 20, 2002·Blood·Hervé DombretUNKNOWN Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group)
Apr 15, 2003·Bone Marrow Transplantation·I Avivi, A H Goldstone
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mirna GolemovicMiloslav Beran
Jul 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Todd A CarterDavid J Lockhart
Nov 24, 2005·Hematology·Oliver G Ottmann, Barbara Wassmann
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Mar 27, 2007·Clinical Lymphoma & Myeloma·Tariq I Mughal, John M Goldman
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael BraveRichard Pazdur

❮ Previous
Next ❯

Citations

Aug 29, 2009·Current Opinion in Oncology·Ryan J Mattison, Richard A Larson
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anthony S SteinStephen J Forman
Apr 20, 2017·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Martin CernanZuzana Pikalova
Aug 8, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Sindhura Lakshmi Koulmane LaxminarayanaKarthik Udupa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.